secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001093557-24-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dexcom Q4 2023 revenue $1.03B, up 27%; GAAP EPS $0.62; FY2024 guidance $4.15-4.35B
--------------------------------------------------------------------------------

- Q4 2023 revenue $1.03B (+27% YoY); GAAP operating income $216.9M (21.0% margin).
- GAAP net income $256.3M ($0.62 diluted EPS) vs $91.8M ($0.22) in Q4 2022.
- Full-year 2023 revenue $3.62B (+24% YoY); GAAP operating margin 16.5% (+310 bps).
- 2024 guidance: revenue $4.15-4.35B (16-21% organic growth); non-GAAP op margin ~20%.
- Submitted Stelo glucose sensor for type 2 diabetes (non-insulin) and direct-to-watch feature to FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355724000020/0001093557-24-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355724000020/dxcm-20240208.htm
  HTML page:      https://secwatch.observer/filing/0001093557-24-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer